MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jnnp-2025-336208

Медицинская библиотека · Journal of neurology, neurosurgery, and psychiatry · 2025

CSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival.

Verde Federico, Vávra Jakub, Dorst J, Elmas Zeynep, Wiesenfarth Maximilian, De Gobbi Anna, Ratti Antonia, Poletti Barbara, Tumani Hayrettin, Weishaupt Jochen, Silani Vincenzo, Ticozzi Nicola, Otto Markus, Ludolph Albert C, Oeckl Patrick

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Previous proteomic work has identified the somatodendritic protein MAP2 as a new candidate cerebrospinal fluid (CSF) biomarker for amyotrophic lateral sclerosis (ALS).

METHODS

We measured CSF levels of MAP2 and neurofilament light chain (NFL) in a retrospective cohort of 251 patients with ALS and 108 neurological controls (NCs).

RESULTS

Patients with ALS had a higher median CSF MAP2 level compared with NCs, leading to an area under the curve (AUC) of 0.7080 (p<0.0001). They also had a higher median CSF NFL level (p<0.0001), resulting in an excellent diagnostic performance (AUC=0.9641; p<0.0001). Among patients with ALS, CSF MAP2 correlated with disease progression rate (DPR) (r=0.3099; p<0.0001) and was negatively associated with survival (HR=3.174). CSF NFL also correlated with DPR (r=0.4936; p<0.0001) and was negatively associated with survival (HR=2.759). The association of MAP2 with DPR was independent from NFL (p=0.0037). Stratifying patients based on median levels of both biomarkers resulted in significant differences in median survival times (low NFL/low MAP2, 66 months; high NFL/low MAP2 and vice versa, 35 months; high NFL/high MAP2, 26 months; p<0.0001). MAP2 was also associated with genetic status in patients with ALS, as patients with no mutations in C9ORF72 or in SOD1, as well as C9ORF72-positive ones, had higher median levels compared with NCs (p<0.0001), while patients with SOD1 mutations did not significantly differ from NCs (p>0.9999).

CONCLUSIONS

Our study shows that the somatodendritic protein MAP2 is a promising candidate CSF biomarker for ALS.

Для цитирования: Verde Federico, Vávra Jakub, Dorst J, Elmas Zeynep, Wiesenfarth Maximilian, De Gobbi Anna, Ratti Antonia, Poletti Barbara, Tumani Hayrettin, Weishaupt Jochen, Silani Vincenzo, Ticozzi Nicola, Otto Markus, Ludolph Albert C, Oeckl Patrick. CSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival.. Journal of neurology, neurosurgery, and psychiatry. 2025. DOI: 10.1136/jnnp-2025-336208.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.